Health Information Portal (HIP)

Search
0 results

No results, please enter a search term above

HAI/AR Surveillance Data Reports

The Philadelphia Department of Public Health (PDPH) HAI/AR Program conducts year-round surveillance for multiple drug-resistant organisms of public health concern by collecting clinical and laboratory information from healthcare facilities. The HAI/AR Program also monitors and tracks numerous healthcare-associated infections and metrics that are reported into the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN), the nation’s most widely used healthcare-associated infections tracking system.

Posting of this data is intended for the purpose of promoting the health of Philadelphia residents and for providing a reference to healthcare providers citywide to inform practice in their own institutions. PDPH attempts to post timely and reliable information, but due to the limitations of the surveillance systems used to generate these data, we cannot guarantee that all data is complete or up-to-date.

Quarter 4: October - December 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases: October - December 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

30 (54%)

Non-CP CRE

17 (30%)

CP Status Pending / Not Tested

9 (16%)

Total Confirmed CRE Cases

56

CRE Cases by Carbapenemase-Producing (CP) Status: January 2022 - December 2022

Q4 CRE

Candida auris Cases in Philadelphia by Month

CAurisQ4

Quarter 3: July - September 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases: July - September 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

28 (57%)

Non-CP CRE

13 (27%)

CP Status Pending / Not Tested

8 (16%)

Total Confirmed CRE Cases

49

Quarter 2: April - June 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases: April - June 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

25 (66%)

Non-CP CRE

7 (18%)

CP Status Pending / Not Tested

6 (16%)

Total Confirmed CRE Cases

38

Quarter 1: January - March 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases: January - March 2022

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

28 (60%)

Non-CP CRE

12 (25%)

CP Status Pending / Not Tested

7 (15%)

Total Confirmed CRE Cases

47